Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Clavulanic acid + dexamethasone is a non-standard combination of a beta-lactamase inhibitor and a corticosteroid. Clavulanic acid is a suicide inhibitor of bacterial beta-lactamase enzymes, typically used in combination with beta-lactam antibiotics like amoxicillin to prevent antibiotic resistance. Dexamethasone is a potent synthetic glucocorticoid used for its anti-inflammatory and immunosuppressive properties. There is no evidence of a commercially available or clinical-stage fixed-dose combination containing only these two ingredients. The mention of this combination likely results from a misinterpretation of the brand name **CLAVODEX**, which is a generic formulation of amoxicillin and clavulanic acid marketed by Dexon Biotech; in this instance, the **DEX** suffix is derived from the company name rather than an indication of dexamethasone content.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on clavulanic acid + dexamethasone.